Alliance Global lowered the firm’s price target on Theriva Biologics (TOVX) to $4 from $7 and keeps a Buy rating on the shares following the Q4 report. The firm cites the increase in Theriva’s share count for the target cut.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX: